These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 10975963)

  • 61. Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients.
    Kazanjian P; Tashima K; Hollander T; Kaul D
    HIV Clin Trials; 2001; 2(3):213-8. PubMed ID: 11590530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
    de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP;
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 65. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
    Dalod M; Harzic M; Pellegrin I; Dumon B; Hoen B; Sereni D; Deschemin JC; Levy JP; Venet A; Gomard E
    J Infect Dis; 1998 Jul; 178(1):61-9. PubMed ID: 9652424
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
    Lederman MM; Connick E; Landay A; Kuritzkes DR; Spritzler J; St Clair M; Kotzin BL; Fox L; Chiozzi MH; Leonard JM; Rousseau F; Wade M; Roe JD; Martinez A; Kessler H
    J Infect Dis; 1998 Jul; 178(1):70-9. PubMed ID: 9652425
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals.
    Greenbaum AH; Wilson LE; Keruly JC; Moore RD; Gebo KA
    AIDS; 2008 Nov; 22(17):2331-9. PubMed ID: 18981772
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy.
    Rigaud M; Borkowsky W; Muresan P; Weinberg A; Larussa P; Fenton T; Read JS; Jean-Philippe P; Fergusson E; Zimmer B; Smith D; Kraimer J;
    J Infect Dis; 2008 Oct; 198(8):1123-30. PubMed ID: 18752430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Two-year clinical and immune outcomes in human immunodeficiency virus-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy.
    Ghaffari G; Passalacqua DJ; Caicedo JL; Goodenow MM; Sleasman JW
    Pediatrics; 2004 Nov; 114(5):e604-11. PubMed ID: 15492356
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
    Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
    Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
    Autran B; Carcelain G; Li TS; Blanc C; Mathez D; Tubiana R; Katlama C; Debré P; Leibowitch J
    Science; 1997 Jul; 277(5322):112-6. PubMed ID: 9204894
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
    Miller V; Sabin CA; Phillips AN; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm EB; Staszewski S
    AIDS; 2000 Sep; 14(14):2129-36. PubMed ID: 11061654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
    Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
    AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High levels of drug-resistant human immunodeficiency virus variants in patients exhibiting increasing CD4+ T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy.
    Bélec L; Piketty C; Si-Mohamed A; Goujon C; Hallouin MC; Cotigny S; Weiss L; Kazatchkine MD
    J Infect Dis; 2000 May; 181(5):1808-12. PubMed ID: 10823790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
    Chun TW; Engel D; Berrey MM; Shea T; Corey L; Fauci AS
    Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8869-73. PubMed ID: 9671771
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.
    Jevtović DJ; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2005 Mar; 6(2):140-3. PubMed ID: 15807721
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
    Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.